Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against Telix Pharmaceuticals Limited regarding possible violations of federal securities laws and unlawful business practices [1][2] - The investigation is aimed at stockholders who have suffered losses from their investments in Telix [1][2] - Telix's stock price experienced a significant decline following the announcement of a subpoena from the U.S. Securities and Exchange Commission, which sought documents related to the company's prostate cancer therapeutic candidates [5] Investigation Details - Investors who purchased Telix shares and incurred losses are encouraged to contact Bragar Eagel & Squire for more information about their legal rights and potential claims [2] - The law firm emphasizes that there is no cost or obligation for investors to inquire about their rights [2] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, specializing in representing individual and institutional investors in complex litigation [3] - The firm handles cases in both state and federal courts across the country [3]
TELIX PHARMACEUTICALS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Stockholders of the Ongoing Investigation